Abstract: A skin care agent and cosmetic and/or dermopharmaceutical compositions involving selectively polygallate molecule either singly or as a synergistic mixture of a polygallate molecule and a gallic acid ester in an effective amount along with an acceptable vehicle with or without other skin benefit agents. Preferably, the active mixture or ingredients is selectively obtained by appropriate combination of suitable sources including plants rich in individual ingredients or a single source such as the skin and/or kernel of Mangifera indica Linn.

Abstract: The present invention relates to the use of standardized extract of Tinospora cordifolia as an immunoadjuvant in the treatment of renal disorders such as nephrotic syndrome and chronic recurrent urinary tract infections, both complicated and uncomplicated. The present invention also relates to pharmaceutical compositions comprising the standardized extract of Tinospora cordifolia. The present invention further relates to a method of treatment of renal disorders such as recurrent urinary tract infection particularly occurring due to relapsing E. coli, Klebsiella and other gram negative infections and to a method of treatment of nephrotic syndrome using standardized extract of Tinospora cordifolia as an immunoadjuvant in conjunction with conventional therapy.

Abstract: The present invention relates to the use of standardized extract of Tinospora cordifolia as an immunoadjuvant in the treatment of renal disorders such as nephrotic syndrome and chronic recurrent urinary tract infections, both complicated and uncomplicated. The present invention also relates to pharmaceutical compositions comprising the standardized extract of Tinospora cordifolia. The present invention further relates to a method of treatment of renal disorders such as recurrent urinary tract infection particularly occurring due to relapsing E. coli, Klebsiella and other gram negative infections and to a method of treatment of nephrotic syndrome using standardized extract of Tinospora cordifolia as an immunoadjuvant in conjunction with conventional therapy.

Abstract: The present invention relates to novel crystalline glucosamine sulphate metal salts for use in the treatment of acute and chronic forms of rheumatic and arthritic diseases and of all the pathological conditions originating from metabolic disorders of the osteo-articular tissues. More particularly, the present invention relates to novel crystalline glucosamine sulphate metal salts having low metal content wherein the metal may be either sodium or potassium. The present invention further relates to a solution-based and a solvent-free process for the preparation of the novel crystalline glucosamine sulphate metal salts having low metal content and to pharmaceutical compositions comprising the novel crystalline glucosamine sulphate metal salts having low metal content.

Abstract: The invention relates to a process for the conversion of echinocandin class of peptides to their C4-homotyrosine monodeoxy analogues, particularly mulundocandin to deoxymulundocandin, which consists of a single step selective reduction of C4-htyr (homotyrosine) hydroxyl group of echinocandins to their monodeoxy analogues under neutral conditions without prior protection/deprotection of the equally facile C5-Orn (ornithine) hydroxyl group and purification of the monodeoxy compound from the crude reaction mixture.

Abstract: The present invention relates to novel crystalline glucosamine sulphate metal salts for use in the treatment of acute and chronic forms of rheumatic and arthritic diseases and of all the pathological conditions originating from metabolic disorders of the osteo-articular tissues. More particularly, the present invention relates to novel crystalline glucosamine sulphate metal salts having low metal content wherein the metal may be either sodium or potassium. The present invention further relates to a solution-based and a solvent-free process for the preparation of the novel crystalline glucosamine sulphate metal salts having low metal content and to pharmaceutical compositions comprising the novel crystalline glucosamine sulphate metal salts having low metal content.

Abstract: Deoxymulundocandin, a compound of the formula I (SEQ. ID NO: 1) ##STR1## has an antiyeast, an antifungal and an immunomodulatory action.

Abstract: Aranorosinol-A and Aranorosinol-B are compounds of the formula ##STR1## in which R is H (Aranorosinol-A) or CH.sub.2 COCH.sub.3 (Aranorosinol-B); said compounds have antibacterial and antifungal activity.

Abstract: A new antibiotic, aranorosin, a microbiological process for the preparation thereof, and the use thereof as a pharmaceutical.Aranorosin, a compound of the formula ##STR1## can be prepared with the aid of the fungus culture Y-30499 (DSM 4151). Aranorosin has an antibiotic action as well as an action against malignant tumors.

Abstract: Fumifungin, a compound of the formula ##STR1## can be isolated from the culture broth of fungus culture No. Y-83,0405 (DSM 4152), and has bactericidal and fungicidal properties.

Abstract: The present invention relates to the compound naphthomycin H of the formula I ##STR1## and to a microbiological process for its preparation. The compound is active against Gram-positive bacteria and fungi and can be used as an antibiotic.